论文部分内容阅读
本文共选择在外院经１次以上治疗后又转移复发的恶性黑色瘤４１例。全组中位生存时间２０．２个月，２年生存率５３．６％，５年生存率４．８％。手术结合瘤苗治疗２７例，单纯手术治疗１４例，前者中位生存时间明显长于后者，３４．３个月和１７．５个月（Ｐ＝０．０００１）。全组完全数据３３例，截尾数据８例（８０．４８％，１９．５％）。肿瘤患者的年龄、性别、大小及肿瘤部位在２组中的分布无差别（Ｐ＝０．９９，Ｐ＝０．１９，Ｐ＝０．５７）。在生存分布上下列诸因素间无差异：年龄Ｐ＝０．４３，性别Ｐ＝０．４，部位Ｐ＝０．７２。结果分析显示恶性黑色素瘤患者生存时间与肿瘤的大小及是否使用瘤苗有关。
In this study, 41 cases of metastatic malignant tumors that had undergone metastasis and recurrence after treatment in the external hospital were selected. The overall median survival time was 20.2 months, the 2-year survival rate was 53.6%, and the 5-year survival rate was 4.8%. Twenty-seven patients underwent surgery combined with tumor vaccines and 14 underwent surgery alone. The median survival time of the former was significantly longer than that of the latter, 34.3 months and 17.5 months (P=0.0001). There were 33 cases of complete data in the whole group and 8 cases of censored data (80.48%, 19.5%). There was no difference in the distribution of age, gender, size, and location of tumors among the two groups (P = 0.99, P = 0.19, P = 0.57). There were no differences among the following factors in survival distribution: age P=0.43, gender P=0.4, and site P=0.72. Analysis of the results showed that the survival time of malignant melanoma patients was related to the size of the tumor and whether or not it was used.